Traders should monitor upcoming regulatory feedback and initiation of the PSP Phase 1b trial as near-term catalysts. Positive momentum in ARV-102 could re-rate the stock, especially given lack of current treatments targeting LRRK2 or lysosomal dysfunction in PSP.
Price Chart
Executive Summary
Arvinas presented positive Phase 1 data for ARV-102, showing approximately 50% or greater reduction of LRRK2 in cerebrospinal fluid in Parkinson’s patients, with good tolerability and biomarker improvements. The company plans to initiate a Phase 1b trial in progressive supranuclear palsy (PSP) in Q2 2026, pending regulatory feedback, supporting further development in neurodegenerative diseases.
Key Facts
- ARV-102 achieved ≥50% LRRK2 reduction in CSF by day 14 and sustained through day 28 across all dose levels (20–80 mg) in Parkinson’s patients
- ARV-102 demonstrated dose-dependent brain penetration and reduction of endolysosomal and neuroinflammatory biomarkers (e.g., CD68, GPNMB)
- No serious adverse events (SAEs) were reported; drug was well tolerated over 28 days
- Arvinas plans to initiate a Phase 1b trial in PSP in Q2 2026, with potential registrational trial by late 2026
- Data presented at AD/PD™ 2026 conference, adding scientific credibility
Financial Impact
No direct financial impact yet; clinical advancement increases probability of success and future revenue potential in high-unmet-need neurodegenerative markets
Risk Factors
- Phase 1 biomarker data does not guarantee clinical efficacy in later trials
- Regulatory delays could push back Phase 1b initiation in PSP
- Competitive landscape may evolve with other LRRK2 inhibitors or tau-targeted therapies
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3258013 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Sep 4, 2026 28d ago | 144 | $9.08 $8.26 | ▼ −9.03% | ▼ −7.91% | $7.41 (−18.39%) |
Jun 22, 2026 14w ago | 8-K | $8.14 $8.29 | ▲ +1.84% | ▲ +0.83% | $7.41 (−8.97%) |
Jun 2, 2026 17w ago | 8-K | $7.70 $6.98 | ▲ +9.35% | ▲ +5.53% | $7.41 (+3.77%) |
May 12, 2026 20w ago | 8-K | $9.57 $8.78 | ▼ −8.26% | ▼ −8.33% | $7.41 (−22.57%) |
May 12, 2026 20w ago | 8-K | $9.57 $8.78 | ▼ −8.26% | ▼ −8.33% | $7.41 (−22.57%) |
May 12, 2026 20w ago | Press Release | $9.57 $8.78 | ▲ +8.26% | ▲ +8.33% | $7.41 (+22.57%) |
May 8, 2026 20w ago | 144 | $9.66 $8.78 | ▼ −9.11% | ▼ −9.02% | $7.41 (−23.29%) |
May 8, 2026 20w ago | 144 | $9.66 $8.78 | ▼ −9.11% | ▼ −9.02% | $7.41 (−23.29%) |
May 5, 2026 21w ago | Press Release | $10.61 $9.57 | ▲ +9.80% | ▲ +11.79% | $7.41 (+30.16%) |
May 1, 2026 22w ago | 8-K | $10.51 $10.19 | ▼ −3.04% | ▼ −5.39% | $7.41 (−29.50%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access